Osteopontin as a Biomarker in Chronic Kidney Disease

Osteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammatio...

Full description

Bibliographic Details
Main Authors: Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, Robert Damoiseaux, Susanne B. Nicholas
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/11/5/1356
_version_ 1827741975843962880
author Satyesh K. Sinha
Michael Mellody
Maria Beatriz Carpio
Robert Damoiseaux
Susanne B. Nicholas
author_facet Satyesh K. Sinha
Michael Mellody
Maria Beatriz Carpio
Robert Damoiseaux
Susanne B. Nicholas
author_sort Satyesh K. Sinha
collection DOAJ
description Osteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammation and fibrosis and regulates calcium and phosphate metabolism. OPN expression is increased in the kidneys, blood, and urine of patients with CKD, particularly in those with diabetic kidney disease and glomerulonephritis. The full-length OPN protein is cleaved by various proteases, including thrombin, matrix metalloproteinase (MMP)-3, MMP-7, cathepsin-D, and plasmin, producing N-terminal OPN (ntOPN), which may have more detrimental effects in CKD. Studies suggest that OPN may serve as a biomarker in CKD, and while more research is needed to fully evaluate and validate OPN and ntOPN as CKD biomarkers, the available evidence suggests that they are promising candidates for further investigation. Targeting OPN may be a potential treatment strategy. Several studies show that inhibition of OPN expression or activity can attenuate kidney injury and improve kidney function. In addition to its effects on kidney function, OPN has been linked to cardiovascular disease, which is a major cause of morbidity and mortality in patients with CKD.
first_indexed 2024-03-11T03:54:47Z
format Article
id doaj.art-76b702ed3c0f436ab97d9577ce5340bb
institution Directory Open Access Journal
issn 2227-9059
language English
last_indexed 2024-03-11T03:54:47Z
publishDate 2023-05-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj.art-76b702ed3c0f436ab97d9577ce5340bb2023-11-18T00:35:50ZengMDPI AGBiomedicines2227-90592023-05-01115135610.3390/biomedicines11051356Osteopontin as a Biomarker in Chronic Kidney DiseaseSatyesh K. Sinha0Michael Mellody1Maria Beatriz Carpio2Robert Damoiseaux3Susanne B. Nicholas4Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USADepartment of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, CA 90095, USADepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USADepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USADepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USAOsteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammation and fibrosis and regulates calcium and phosphate metabolism. OPN expression is increased in the kidneys, blood, and urine of patients with CKD, particularly in those with diabetic kidney disease and glomerulonephritis. The full-length OPN protein is cleaved by various proteases, including thrombin, matrix metalloproteinase (MMP)-3, MMP-7, cathepsin-D, and plasmin, producing N-terminal OPN (ntOPN), which may have more detrimental effects in CKD. Studies suggest that OPN may serve as a biomarker in CKD, and while more research is needed to fully evaluate and validate OPN and ntOPN as CKD biomarkers, the available evidence suggests that they are promising candidates for further investigation. Targeting OPN may be a potential treatment strategy. Several studies show that inhibition of OPN expression or activity can attenuate kidney injury and improve kidney function. In addition to its effects on kidney function, OPN has been linked to cardiovascular disease, which is a major cause of morbidity and mortality in patients with CKD.https://www.mdpi.com/2227-9059/11/5/1356osteopontinN-terminal osteopontinchronic kidney diseasediabetic kidney diseasebiomarker
spellingShingle Satyesh K. Sinha
Michael Mellody
Maria Beatriz Carpio
Robert Damoiseaux
Susanne B. Nicholas
Osteopontin as a Biomarker in Chronic Kidney Disease
Biomedicines
osteopontin
N-terminal osteopontin
chronic kidney disease
diabetic kidney disease
biomarker
title Osteopontin as a Biomarker in Chronic Kidney Disease
title_full Osteopontin as a Biomarker in Chronic Kidney Disease
title_fullStr Osteopontin as a Biomarker in Chronic Kidney Disease
title_full_unstemmed Osteopontin as a Biomarker in Chronic Kidney Disease
title_short Osteopontin as a Biomarker in Chronic Kidney Disease
title_sort osteopontin as a biomarker in chronic kidney disease
topic osteopontin
N-terminal osteopontin
chronic kidney disease
diabetic kidney disease
biomarker
url https://www.mdpi.com/2227-9059/11/5/1356
work_keys_str_mv AT satyeshksinha osteopontinasabiomarkerinchronickidneydisease
AT michaelmellody osteopontinasabiomarkerinchronickidneydisease
AT mariabeatrizcarpio osteopontinasabiomarkerinchronickidneydisease
AT robertdamoiseaux osteopontinasabiomarkerinchronickidneydisease
AT susannebnicholas osteopontinasabiomarkerinchronickidneydisease